Xeris Biopharma Holdings Inc（XERS）の財務XERSXeris Biopharma Holdings Inc

Xeris Biopharma Holdings, Inc. (XERS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Product revenue -Recorlev, accounting for 61.6% of total sales, equivalent to $56.78M. Other significant revenue streams include Product revenue - Gvoke and Product revenue - Keveyis. Understanding this composition is critical for investors evaluating how XERS navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Xeris Biopharma Holdings, Inc. maintains a gross margin of 83.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 5.62%, while the net margin is -33.77%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively XERS converts its operational activities into shareholder value.

In the context of the broader market, XERS competes directly with industry leaders such as NVAX and FRNM. With a market capitalization of $1.55B, it holds a significant position in the sector. When comparing efficiency, XERS's gross margin of 83.47% stands against NVAX's 78.93% and FRNM's N/A. Such benchmarking helps identify whether Xeris Biopharma Holdings, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown strong revenue growth, with Q2 2026 revenue at $92 million, a 28.7% increase from the previous year. Gross margins have improved to 87%, indicating better profitability.